주요 내용으로 건너 뛰기
/ 뉴스 / Certara Establishes Certainty Conference in Europe, Creating Space for Drug Development Leaders to Convene

Certara Establishes Certainty Conference in Europe, Creating Space for Drug Development Leaders to Convene

Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development  

RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in model-informed drug development, today announced that it is continuing to scale its premier client summit Certainty in Europe. Prior Certainty events have happened in the US and Asia-Pacific regions. Certainty EU will take place in Germany on October 29-30, 2024. 

“Connecting with clients and partners around the globe is pivotal to how we continue advancing our mission of transforming drug discovery and development. We’re creating spaces where likeminded drug developers discuss success stories, opportunities, and challenges so together we can deliver products, solutions, and expertise that truly make a difference,” said William F. Feehery, CEO of Certara. 

Certara is offering exclusive access to its experts and industry peers to network and innovate on advancing drug development and discovery with technology. Designed with pharmacometricians, clinical pharmacologists, regulatory science professionals, biostatisticians, and data scientists in mind, the event will explore where model-informed drug development is headed along with unique customer case studies, insights, best practices and more. Featured sessions include:  

  • Delivering Greater Certainty to Drug Development from Molecule to Market with Certara
    Featuring William Feehery, PhD, CEO, Certara
  • Medicines that Matter: How Biosimulation Supported FDA Approval for Duchenne Muscular Dystrophy Treatment in Children
    Featuring Francesco Bellanti, Sr. Director, Certara, & Paolo Bettica, MD, PhD, CMO, Italfarmaco
  • Impact of Model-Informed Drug Development on Strategic Decision Making
    Featuring Piet Van Der Graaf, PharmD, PhD, SVP, Certara; Andreas Wallnofer, Pharma & Biotech executive & Simon Westbrook, PhD, CSO, Levicept Ltd
  • Speeding Time to Insights with Digital Data Flow, Automation and Analytics
    A panel discussion featuring Esther Vock, PhD, Director, Global Nonclinical Safety & DMPK, Boehringer Ingelheim, and Matthieu Chaton, Team Lead, Data Quality, UCB
  • Generative AI for Regulatory Writing and the Impact of Generative AI for Insight Generation in Nonclinical Development
    featuring Nick Brown, Global Portfolio Leader, Certara, and Thibault Geoui, PhD, MBA, Charles River Laboratories

The event continues for further exploration for in-depth community discussions for Certara’s core product offerings and solution suites: 

  • Pinnacle 21 clinical data management and automation suite,
  • Phoenix pharmacokinetic/pharmacodynamic analysis platform, and
  • Model-informed drug development for pre-clinical and clinical development.

The tracks will allow customers to learn directly from product owners about what’s new, customer stories, and the roadmaps heading into 2025.  

For more information about Certainty Europe, please visit: http://certainty.certara.com/agenda-europe.  

Certara 소개 

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. 2,30070 Certara의 고객으로는 전 세계 62개국에 걸쳐 2,000개 이상의 글로벌 바이오 제약 회사, 선도적인 학술 기관 및 주요 규제기관들이 있다. Visit us at www.certara.com

Certara Contact: 
Sheila Rocchio 
sheila.rocchio@certara.com  

Media Contact: 
Alyssa Horowitz 
PAN Communications
certara@pancomm.com

Powered by Translations.com GlobalLink Web Software